UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.  C.  20549

                                 Form 10-QSB


[X]   Quarterly Report Under Section 13 or 15(d) of the Securities Exchange
      Act of 1934

                       For Quarter Ended: June 30, 2001

                                      OR

[ ]   Transition Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934



                        Commission File No.  000-30991

                   SKINOVATION PHARMACEUTICAL INCORPORATED
                     (Name of registrant in its charter)


          NEVADA                                         87-0458170
  (State of incorporation)          (I. R. S. Employer Identification No.)

                              525 SOUTH 300 EAST
                          SALT LAKE CITY, UTAH 84111
                                (801) 323-2395
        (Address and telephone number of principal executive offices
                       and principal place of business)



     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes [X]   No [   ]

     As of July 20, 2001, the Registrant had a total of 708,000 shares of
common stock issued and outstanding.

<PAGE>

                                    PART I
                            FINANCIAL INFORMATION


ITEM 1: FINANCIAL STATEMENTS

     The financial information set forth below with respect to our statements
of operations for the three and six month periods ended June 30, 2001 and 2000
is unaudited.  This financial information, in the opinion of management,
includes all adjustments consisting of normal recurring entries necessary for
the fair presentation of such data.  The results of operations for the six
months ended June 30, 2001, are not necessarily indicative of results to be
expected for any subsequent period.

<PAGE> 2



                       Skinovation Pharmaceutical, Inc.
                        (A Development Stage Company)
                             Financial Statements
                                June 30, 2001

<PAGE> 3


                       Skinovation Pharmaceutical, Inc.
                        (A Development Stage Company)
                                Balance Sheets



                                    ASSETS
                                                   June 30,      December 31,
                                                   2001          2000
                                                   ------------- -------------
                                                   (Unaudited)

CURRENT ASSETS                                     $          -  $          -
                                                   ------------- -------------

  TOTAL ASSETS                                     $          -  $          -
                                                   ============= =============


                     LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related Party                   $     28,776  $     28,776
                                                   ------------- -------------

  Total Liabilities                                      28,776        28,776
                                                   ------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000 shares
  authorized; 708,000 shares issued and
  outstanding, respectively                                 708           708

Additional Paid in Capital                               25,148        25,148

Deficit Accumulated During the Development Stage        (54,632)      (54,632)
                                                   ------------- -------------

  Total Stockholders' Equity                            (28,776)      (28,776)
                                                   ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY       $          -  $          -
                                                   ============= =============


                                     F-1

<PAGE> 4


                       Skinovation Pharmaceutical, Inc.
                        (A Development Stage Company)
                           Statement of Operations
                                 (Unaudited)

<TABLE>
<CAPTION>


                                                                                           From
                               For the        For the        For the        For the        Inception on
                               three months   three months   six months     six months     January 15, 1988
                               ended June 30, ended June 30, ended June 30, ended June 30, to June 30,
                               2001           2000           2001           2000           2001
                               -------------- -------------- -------------- -------------- --------------
<S>                            <C>            <C>            <C>            <C>            <C>
REVENUES                       $           -  $           -  $           -  $           -  $      27,937
                               -------------- -------------- -------------- -------------- --------------
EXPENSES
  General & Administrative                 -              -              -              -        119,644
                               -------------- -------------- -------------- -------------- --------------

    TOTAL EXPENSES                         -              -              -              -        119,644
                               -------------- -------------- -------------- -------------- --------------
NET LOSS BEFORE DISCONTINUED
  OPERATIONS                               -              -              -              -        (91,707)
                               -------------- -------------- -------------- -------------- --------------

GAIN ON DISPOSAL OF OPERATIONS             -              -              -              -         37,075
                               -------------- -------------- -------------- -------------- --------------

NET INCOME(LOSS)               $           -  $           -  $           -  $           -  $     (54,632)
                               ============== ============== ============== ============== ==============

NET LOSS PER SHARE             $           -  $           -  $           -  $           -  $       (0.14)
                               ============== ============== ============== ============== ==============
WEIGHTED AVERAGE SHARES
  OUTSTANDING                        708,000        653,000        708,000        653,000        390,593
                               ============== ============== ============== ============== ==============



                                        F-2



</TABLE>
<PAGE> 5
<TABLE>
<CAPTION>

                         Skinovation Pharmaceutical, Inc.
                           (A Development Stage Company)
                              Statement of Cash Flows
                                    (Unaudited)

                                                                                           From
                                                               For the six months ended    Inception on
                                                                         June 30,          January 15, 1988
                                                                   2001          2000      to June 30, 2001
                                                              -------------- ------------- ---------------
<S>                                                           <C>            <C>           <C>
Cash Flows from Operating Activities

  Net Loss                                                    $           -  $          -  $      (54,632)
  Less Non-Cash Items:
  Shares issued for services                                              -             -          10,433
  Shares issued for debt payment                                          -             -           1,424
  Increase(Decrease) in accounts payable                                  -             -          28,776
  Loss on disposal of PP&E                                                -             -           5,263
                                                              -------------- ------------- ---------------

  Net Cash Provided(Used) by Operating Activities                         -             -          (8,736)
                                                              -------------- ------------- ---------------
Cash Flows from Investing Activities
  Cash paid for PP&E                                                      -             -          (5,264)
                                                              -------------- ------------- ---------------

  Net Cash Provided(Used) by Investing Activities                         -             -          (5,264)
                                                              -------------- ------------- ---------------
Cash Flows from Financing Activities
  Cash paid for offering costs                                            -             -          (7,000)
  Shares issued for cash                                                  -             -          21,000
                                                              -------------- ------------- ---------------

  Net Cash Provided(Used) by Financing Activities                         -             -          14,000
                                                              -------------- ------------- ---------------

Increase in Cash                                                          -             -               -
                                                              -------------- ------------- ---------------

Cash and Cash Equivalents at Beginning of Period                          -             -               -
                                                              -------------- ------------- ---------------

Cash and Cash Equivalents at End of Period                    $           -  $          -  $            -
                                                              ============== ============= ===============

Supplemental Non-Cash Financing Transactions:

  Stock issued for debt payment                               $           -  $          -  $        1,424
  Stock issued for services                                   $           -  $          -  $       10,433

Cash Paid For:
  Interest                                                    $           -  $          -  $            -
  Income Taxes                                                $           -  $          -  $            -


                                        F-3
</TABLE>
<PAGE> 6


                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                Notes to the Financial Statements
                          June 30, 2001



GENERAL

Skinovation Pharmaceutical, Inc.(the Company) has elected to omit
substantially all footnotes to the financial statements for the six months
ended June 30, 2001 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report  filed on Form 10-KSB for the year ended
December 31, 2000.

UNAUDITED INFORMATION

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are of a normal recurring nature and are, in the opinion of management,
necessary to properly reflect the results of the interim period presented.
The information presented is not necessarily indicative of the results from
operations expected for the full fiscal year.

                               F-4

<PAGE> 7

     In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

                    Forward Looking Statements

     This Form 10-QSB contains certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.  For this
purpose any statements contained in this Form 10-QSB that are not statements
of historical fact may be deemed to be forward-looking statements.  Without
limiting the foregoing, words such as "may," "will," "expect," "believe,"
"anticipate," "estimate" or "continue" or comparable terminology are intended
to identify forward-looking statements.  These statements by their nature
involve substantial risks and uncertainties, and actual results may differ
materially depending on a variety of factors, many of which are not within
Skinovation's control.  These factors include but are not limited to economic
conditions generally and in the market which Skinovation may participate;
competition within Skinovation's chosen market and failure by Skinovation to
successfully develop business relationships.

ITEM 2:  PLAN OF OPERATIONS

     We are a development stage company with no assets and we have experienced
losses since our inception.  We are dependent on financing to continue our
operations.  For the fiscal year ended December 31, 2000, and the six and
three month periods ended June 30, 2001, we had no cash on hand and total
current liabilities of $28,776.  The $28,766 account payable is related to
accounting and legal fees paid on our behalf by a related party in fiscal year
1999.

     We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  We may
repay these loans, costs of services  and advancements with cash, if
available, or we may convert them into common stock.  Also, management
anticipates future private placements of our common shares may fund our
operations.

     We will incur expenses due to the legal and accounting services required
to prepare and file reports with the Securities and Exchange Commission.
Also, our management must expend time and effort to assist in the preparation
and review of such reports.  We anticipate that such expenses will be paid for
by loans or equity transactions.  In the event we acquire a business
opportunity we may incur additional expenses related to proxy or information
statements we must provide to our stockholders which disclose that company's
business operations, management and financial condition.  In addition, the
acquired or merged company will be subject to these same reporting
obligations.

     Our management intends to actively pursue business opportunities during
the next twelve months.  All risks inherent in new and inexperienced
enterprises are inherent in our business.  We have not made a formal study of
the economic potential of any business.  At the present, we have not
identified any assets or business opportunities for acquisition.

     Based on current economic and regulatory conditions, management believes
that it is possible, if not probable, for a company like ours, without many
assets or liabilities, to negotiate a merger or acquisition with a viable
private company.  The opportunity arises principally because of the high legal
and accounting fees and the length of time associated with the registration
process of "going public".

<PAGE> 8

However, should any of these conditions change, it is very possible that there
would be little or no economic value for anyone taking over control of
Skinovation.

     Potential investors must recognize that because of our limited capital
available for investigation and management's limited experience in business
analysis we may not discover or adequately evaluate adverse facts about the
business opportunity to be acquired.  Also, we intend to concentrate our
acquisition efforts on properties or businesses that we believe to be
undervalued or that we believe may realize a substantial benefit from being
publicly owned.  Investors should expect that any acquisition candidate may
have little or no operating history, or a history of losses or low
profitability.

     It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

     Should a merger or acquisition prove unsuccessful, it is possible that we
may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.


                             PART II
                        OTHER INFORMATION

ITEM 5: OTHER EVENTS

     On June 15, 2001, Anita Patterson resigned from her position as our
director in order to pursue other interests.  As a result, we currently have a
vacancy on our board of directors which management expects to fill within the
next 60 days.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a)   Exhibits

Exhibit
Number   Description
-------  ---------------
3.1      Articles of Incorporation, dated January 15, 1988 (Incorporated by
         reference to exhibit 3.1 of the Form-SB, filed July 11, 2000)

3.2      Certificate of Amendment, dated August 5, 1992 (Incorporated by
         reference to exhibit 3.2 of the Form-SB, filed July 11, 2000)

3.3      Bylaws of Skinovation Pharmaceutical Incorporated (Incorporated by
         reference to exhibit 3.3 of the Form-SB, filed July 11, 2000)

(b)  Reports on Form 8-K

     None.

<PAGE> 9


                            SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.


                                Skinovation Pharmaceutical Incorporated


       7/23/01                  /s/ John W. Peters
Date_________________       By: _____________________________________________
                                John W. Peters, President and Director


       7/23/01                  /s/ Jeanne Ball
Date_________________       By: _____________________________________________
                                Jeanne Ball, Secretary/Treasurer and Director





                                10